评论：Jilkova, Z.M.等人，“肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”，2019年，第1554页。
Comment on: Jilkova, Z.M.; et al. "Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.
作者信息
Dunnigan Anna
机构信息
Institute of Clinical Trials and Methodology, University College London, London WC1V 6LJ, UK.
出版信息
Cancers (Basel). 2020 Sep 18;12(9):2670. doi: 10.3390/cancers12092670.
Abstract
I read with interest the article 'Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges' [...].
摘要
我饶有兴趣地阅读了《肝细胞癌领域中对PD-1/PD-L1免疫检查点抑制反应的预测因素：现状与挑战》这篇文章[……]。
相似文献
1
Comment on: Jilkova, Z.M.; et al. "Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.评论：Jilkova, Z.M.等人，“肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”，2019年，第1554页。
Cancers (Basel). 2020 Sep 18;12(9):2670. doi: 10.3390/cancers12092670.
2
Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.对“Jilkova, Z.M.等人。肝细胞癌领域中PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”评论的回复 2019年，，1554
Cancers (Basel). 2020 Sep 18;12(9):2673. doi: 10.3390/cancers12092673.
3
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战
Cancers (Basel). 2019 Oct 14;11(10):1554. doi: 10.3390/cancers11101554.
4
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.免疫检查点抑制剂联合治疗的益处及肿瘤突变负担在肝细胞癌中的预测作用：系统评价和荟萃分析。
Int Immunopharmacol. 2022 Nov;112:109244. doi: 10.1016/j.intimp.2022.109244. Epub 2022 Sep 18.
5
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.PD-1/PD-L1 通路及其免疫检查点抑制剂在人类癌症中的应用。
Front Immunol. 2022 Sep 13;13:964442. doi: 10.3389/fimmu.2022.964442. eCollection 2022.
6
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.调节性 T 细胞和检查点抑制在肝细胞癌中的作用。
Cancer Immunol Immunother. 2019 Dec;68(12):2055-2066. doi: 10.1007/s00262-019-02427-4. Epub 2019 Nov 13.
7
Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.CMTM4 抑制通过 PD-L1 增强胆管癌和肝细胞癌对 T 细胞介导的抗肿瘤免疫。
Hepatol Commun. 2022 Jan;6(1):178-193. doi: 10.1002/hep4.1682. Epub 2021 Jul 21.
8
Current studies of immunotherapy in head and neck cancer.头颈部癌免疫治疗的当前研究。
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
9
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
10
The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.PD-1/PD-L1 抑制剂治疗晚期肝细胞癌患者中 PD-L1 表达的预测价值：系统评价和荟萃分析。
Cancer Med. 2023 Apr;12(8):9282-9292. doi: 10.1002/cam4.5676. Epub 2023 Mar 25.
引用本文的文献
1
Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer.氧化苦参碱通过下调IFN-γ抑制PD-L1，促进肝癌细胞铁死亡并增强抗PD-L1疗效。
J Hepatocell Carcinoma. 2024 Dec 6;11:2427-2440. doi: 10.2147/JHC.S492582. eCollection 2024.
本文引用的文献
1
Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.对“Jilkova, Z.M.等人。肝细胞癌领域中PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”评论的回复 2019年，，1554
Cancers (Basel). 2020 Sep 18;12(9):2673. doi: 10.3390/cancers12092673.
2
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.肿瘤突变负荷作为预测多种癌症免疫治疗反应的独立标志物。
Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.
3
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
Zotero 插件